[responsivevoice_button voice="Hindi Female" buttontext="Listen This News"]
AstraZeneca said on Tuesday
that it is working with Oracle to use AI and real-world
data to identify eligible patients for clinical trials and
monitor safety signals, among other measures, as the drugmaker
looks to improve clinical research.
-
The collaboration will combine AstraZeneca’s drug
development expertise with Oracle’s AI and healthcare data
capabilities to support patient matching and research -
Initial work will focus on cancer, cardiovascular,
respiratory, immunology and rare diseases, and could also
support earlier diagnosis of serious diseases -
The first project will support hypertension research in
Abu Dhabi in partnership with UAE-based healthcare firm M42 -
Patient recruitment remains one of the biggest challenges
in clinical research, with delayed enrolment often extending
trial timelines and increasing development costs -
Incorrect trial designs have also hurt AstraZeneca in the
past, with delays on its breast cancer drug and nerve disorder
treatment failure causing some worries -
AstraZeneca is seeking to expand its medicine portfolio as
it targets over $80 billion in annual revenue by 2030, and works
to address industry bottlenecks in drug development